Literature DB >> 27678382

Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation.

Sophie Caillard1, Camille Becmeur1, Gabriela Gautier-Vargas1, Jerome Olagne1,2, Clotilde Muller1, Noelle Cognard1, Peggy Perrin1, Laura Braun1, Francoise Heibel1, Francois Lefebre3, Veronique Renner4, Christian Gachet4, Bruno Moulin1, Anne Parissiadis4.   

Abstract

Donor-specific antibodies (DSA) increase the risk of allograft rejection and graft failure. They may be present before transplant or develop de novo after transplantation. Here, we studied the evolution of preformed DSA and their impact on graft outcome in kidney transplant recipients. Using the Luminex Single Antigen assay, we analyzed the sera on the day of transplantation of 239 patients who received a kidney transplant. Thirty-seven patients (15.5%) had pre-existing DSA detected the day of transplantation. After 5 years, the pre-existing DSA disappeared in 22 patients whereas they persisted in 12. Variables associated with DSA persistence were age <50 years (P = 0.009), a history of previous transplantation (P = 0.039), the presence of class II DSA (P = 0.009), an MFI of preformed DSA >3500 (P < 0.001), and the presence of two or more DSA (P < 0.001). DSA persistence was associated with a higher risk of graft loss and antibody-mediated rejection. Previously undetected preformed DSA are deleterious to graft survival only when they persist after transplantation.
© 2016 Steunstichting ESOT.

Entities:  

Keywords:  antibody-mediated rejection; donor-specific antibody; graft survival; kidney transplantation

Mesh:

Substances:

Year:  2016        PMID: 27678382     DOI: 10.1111/tri.12864

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  5 in total

1.  Impact of persistent preformed and de novo donor-specific antibodies detected at 1 year after kidney transplantation on long-term graft survival in Japan: a retrospective study.

Authors:  Nobuhiro Fujiyama; Shigeru Satoh; Mitsuru Saito; Kazuyuki Numakura; Takamitsu Inoue; Ryuhei Yamamoto; Takuro Saito; Sohei Kanda; Shintaro Narita; Yoko Mitobe; Tomonori Habuchi
Journal:  Clin Exp Nephrol       Date:  2019-09-06       Impact factor: 2.801

2.  Comparison of Physical Crossmatch and Virtual Crossmatch to Identify Preexisting Donor-Specific Human Leukocyte Antigen (HLA) Antibodies and Outcome Following Kidney Transplantation.

Authors:  Bo Peng; Quan Zhuang; Meng Yu; Junhui Li; Yun Liu; Lijun Zhu; Yingzi Ming
Journal:  Med Sci Monit       Date:  2019-02-03

3.  Class and Kinetics of Weakly Reactive Pretransplant Donor-specific HLA Antibodies Predict Rejection in Kidney Transplant Recipients.

Authors:  Alexander H Morrison; Meera Gupta; Kelsey Lloyd; Jennifer Trofe-Clark; Mary Ann Lim; Christine Limonte; Matthew H Levine; Deirdre Sawinski; Malek Kamoun; Paige M Porrett
Journal:  Transplant Direct       Date:  2019-07-25

Review 4.  Therapies for Chronic Allograft Rejection.

Authors:  Min Young Kim; Daniel C Brennan
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

5.  Predictive Potential of Flow Cytometry Crossmatching in Deceased Donor Kidney Transplant Recipients Subjected to Peritransplant Desensitization.

Authors:  Klara Osickova; Petra Hruba; Katerina Kabrtova; Jiri Klema; Jana Maluskova; Antonij Slavcev; Janka Slatinska; Tomas Marada; Georg A Böhmig; Ondrej Viklicky
Journal:  Front Med (Lausanne)       Date:  2021-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.